Indication: Genitourinary Cancer
An Expanded/Phase 2, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of Proxalutamide (GT0918) in Subjects with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) and Metastatic Castrate Resistant Prostate Cancer (mCRPC) who Failed Either Abiraterone or Enzalutamide
Sub-indication: Progressive disease despite hormonal treatment with abiraterone or enzalutamide, but not both. One line of chemotherapy is eligible
Line of Therapy: 2nd Line
Principal Investigator: Chandler Park, M.D.Norton Cancer Institute
Sponsor: Suzhou Kintor Pharmaceuticals, Inc.
Email for more information: GU-NCIResearch@nortonhealthcare.org